0001789769-26-000019
SEC filingInstil Bio, Inc. reported a net loss of $71.4 million for FY 2025, a slight improvement from a $74.1 million loss in FY 2024. Total operating expenses were $78.6 million, driven by in-process R&D ($10.0M), research and development ($24.7M), general and administrative ($27.2M), and restructuring and impairment charges ($16.6M). The company generated no product revenue and ended the year with $76.3 million in cash, cash equivalents, restricted cash, and marketable securities. Key developments include the discontinuation of lead candidate AXN-2510 in January 2026 and a strategic shift toward in-licensing or acquiring new therapeutic candidates. The company faces a significant debt maturity of $85.6 million in January 2027 but plans to exercise an extension option to January 2028.
Instil Bio reported a net loss of $71.4 million for FY 2025, representing a modest improvement from the $74.1 million net loss in FY 2024. Total operating expenses decreased slightly to $78.6 million from $73.5 million in the prior year. The company generated no product revenue during the period. Key expense drivers included in-process research and development ($10.0 million), research and development ($24.7 million), general and administrative ($27.2 million), and restructuring and impairment charges ($16.6 million). The company ended the fiscal year with $76.3 million in cash, cash equivalents, restricted cash, and marketable securities, consisting of $6.6 million in cash and cash equivalents, $0.2 million in restricted cash, and $69.5 million in marketable securities.
The company generated no product revenue during FY 2025. All income was derived from non-operating sources, including interest income ($3.9 million), other rental income ($9.0 million), and other income ($0.2 million). The company's business model remains focused on identifying and advancing therapeutic opportunities through potential acquisitions or in-licensing, with no commercial products currently generating revenue. In January 2026, the company announced the discontinuation of its former lead product candidate, AXN-2510, following the termination of its collaboration agreement with ImmuneOnco.
As a pre-revenue biotechnology company, Instil Bio reported negative operating margins with a loss from operations of $78.6 million for FY 2025. The company's cost structure showed significant restructuring and impairment charges of $16.6 million, primarily related to asset impairments associated with the Tarzana facility held for sale. Research and development expenses increased to $24.7 million from $11.8 million in the prior year, driven by costs related to the ImmuneOnco collaboration and AXN-2510 clinical trial. General and administrative expenses decreased to $27.2 million from $44.2 million, primarily due to reduced headcount and personnel-related costs.
Net cash used in operating activities was $36.6 million for FY 2025, compared to $55.7 million in the prior year. The company generated $25.5 million from investing activities, primarily from maturities of marketable securities, and $7.3 million from financing activities, mainly from at-the-market offerings. Total assets decreased to $203.5 million from $263.6 million, with current assets of $191.4 million including $112.1 million in assets held for sale. Total liabilities were $89.7 million, including $84.8 million in loan payable. Stockholders' equity stood at $113.9 million. The company's liquidity position includes $76.3 million in cash, cash equivalents, restricted cash, and marketable securities.
Management believes existing cash, cash equivalents, restricted cash, and marketable securities will be sufficient to fund operating expenses and capital expenditure requirements beyond 2027. However, the company faces a significant debt maturity of $85.6 million in January 2027, which exceeds current liquid resources. The company plans to exercise its contractual right to extend the loan maturity to January 2028. Strategic priorities include seeking to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Risk factors include the company's ability to refinance debt, execute business development activities, and navigate intense competition in the biotechnology industry.